Related Experiment Video
Updated: Jul 4, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Changes in peripheral benzodiazepine receptors in patients with bipolar disorder
Donatella Marazziti1, Bernardo Dell'Osso, Stefano Baroni
1Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie University of Pisa Pisa, Italy. dmarazzi@psico.med.unipi.it
Abstract:
Peripheral benzodiazepine (BDZ) receptors were investigated by means of the binding of the specific ligand (3)H-PK 11195 to platelet membranes in patients suffering from bipolar disorder and in healthy controls. The results showed that the density (Bmax) of peripheral BDZ receptors was significantly higher in patients than in control subjects, with no change in the dissociation constant. No correlation with demographic or clinical features was observed. These findings would suggest that alterations of peripheral BDZ receptors are present in patients suffering from bipolar disorder, but it is premature to conclude whether they may be related to the pathophysiology of the disorder, or are secondary to changes occurring in other systems, such as those regulating the stress response.
Related Concept Videos
Bipolar Disorder
Anxiolytic Drugs: Benzodiazepines and Buspirone
Mania and Antimanic Drugs: Overview
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
